Handbook of Pediatric Cardiovascular Drugs

The treatment of pediatric patients with congenital or acquired cardiac disease remains an important challenge for physicians in charge of these often p- carious patients. It is well known that most of the drugs used in this field are either unlicensed or off-label. We have to face a very heterogeneous group of patients not only in pathologies but also in size, weight, and metabolism, p- ticularly when we face problems in premature or newborns. Not only have very few studies offered evidenced-ba